NEW RESEARCH: August 2014 Update on Boston Therapeutics (BTHE)

Posted by Laura Swartz

August 25, 2014 at 11:01 AM

We have published an updated report on pharmaceutical company, Boston Therapeutics, Inc. (BTHE-OTC). The 16-page Quarterly Update covers Boston Therapeutics' financial results for the three- and six-month periods ended June 30, 2014, as well as details recent news releases and pipeline progress since the publication of our previous Quarterly Update on the company in early June.

Read More

Topics: BTHE

NEW Slide Presentation Released for Truett-Hurst, Inc. (THST-NASDAQ)

Posted by Laura Swartz

August 22, 2014 at 3:48 PM

Following the publication earlier this week of a 72-page, comprehensive Executive Informational Overview (EIO) on winemaker Truett-Hurst, Inc. (THST-NASDAQ), we have today released a summary presentation on SlideShare. The presentation is 12 slides and overviews many of the key points about Truett-Hurst and the wine industry, as addressed in detail in the EIO. 

Read More

Topics: Truett-Hurst

NEW RESEARCH: Truett-Hurst (THST-NASDAQ) Innovates the Wine Industry

Posted by Laura Swartz

August 21, 2014 at 3:36 PM

Truett-Hurst Executive Informational Overview CoverWe recently issued a 72-page Executive Informational Overview® (EIO) on California winemaker Truett-Hurst, Inc. (THST-NASDAQ). The EIO details the Company's product lines, business model, growth strategies, market opportunities, future milestones, competitive landscape, financial position, business risks, and more. It is available for download on our website here. Our online summary of Truett-Hurst's five key competitive advantages in the beverage alcohol industry, specifically with regard to wine production and sales, is available at the Truett-Hurst Key Points page here.

Read More

Topics: Truett-Hurst

Dial-in Info for Investor Conference Call with Pressure BioSciences, Inc. ($PBIO)

Posted by Laura Swartz

August 13, 2014 at 11:39 AM

Pressure BioSciences, Inc. (PBIO-OTC), a company that develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market, will hold a conference call to update investors on its business and financial results on Thursday, August 14, 2014. The call will cover the company's financial results for the second quarter 2014.

Read More

Topics: Pressure BioSciences

Are Speed and Performance the Future of Electric Vehicles? They are for Steve Saleen.

Posted by Laura Swartz

August 8, 2014 at 11:51 AM

By now, most people who follow Steve Saleen and his American sports cars business of the same name, Saleen Automotive (SLNN-OTC), know that the company has recently been developing electric vehicle technologies suited for the same American consumers who value the speed and performance of classic muscle cars. In the high-performance sports car and supercar markets that Saleen targets, there is a growing consumer interest in fuel-efficient technologies that are packaged into a well-designed and performance-capable platform. Steve Saleen believes that his company’s skilled engineering, design, and production capabilities give it an competitive advantage in developing fuel-efficient American vehicles that continue to exceed performance specs.
 
Thus, in response to these changing market dynamics, within the past year Saleen has added to its portfolio an EV development program, as described in this article, which is designed to capitalize on the industry’s rapidly growing interest in hybrid technologies with boosted performance. After months of careful R&D, Saleen plans to debut its first-ever electric vehicle, dubbed The Saleen FOURSIXTEEN, on Sunday, August 17, 2014, at the 2014 Pebble Beach Concours d'Elegance in Carmel, California.

Read More

Topics: Saleen

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic